Recent insights into nanostructured lipid carriers for novel drug delivery systems
- 1Uttaranchal Institute of Pharmaceutical Science, Uttaranchal University, Dehradun-248007, India
Abstract
Background: Nanostructured lipid carriers (NLCs) are advanced lipid-based nanocarriers developed to overcome the limitations of conventional drug-delivery systems. Composed of a nanometric matrix of solid and liquid lipids, NLCs offer improved stability, safety, and drug-loading efficiency compared with other lipid, polymeric, or metallic nanoparticles. Their biocompatibility and non-toxicity make them attractive for pharmaceutical and biomedical applications. Methodology: This review systematically summarizes recent literature on NLC design, classification, structural characteristics, and preparation techniques. It discusses widely used formulation methods for lipid-based nanocarriers and strategies for surface modification to achieve targeted delivery and prolonged residence time. Results and Discussion: Nanostructured lipid carriers (NLCs) show high drug encapsulation efficiency, typically 70–95%, about 20–30% higher than conventional solid lipid nanoparticles (SLNs). Furthermore, NLCs enhance physicochemical stability, improve permeability, and increase the solubility of both hydrophilic and lipophilic drugs. Surface functionalization strategies enable controlled drug release and targeted delivery, thereby significantly improving therapeutic outcomes across multiple routes of administration. Because they can enhance bioavailability and protect encapsulated agents, NLCs are particularly well-suited for challenging delivery routes. Their versatility supports applications across a wide range of diseases, including infections, diabetes, cancer, neurodegenerative disorders, hypertension, and pain management. Conclusion: Overall, NLCs are a promising, versatile platform for safe and effective drug and gene delivery. Continued research and optimization may further expand their clinical potential across diverse therapeutic areas.
Related
- Neuroprotection after transient middle cerebral artery occlusion in male rats using kojic acid nanostructured lipid carriers: A behavioral, biochemical, and histological study on hippocampal CA1 region
- Nanostructured Lipid Carriers Coenzyme Q10 with Stearic Acid as Solid Lipid Phase and Nyamplung Oil (Calophyllum inophyllum L.) as Liquid Lipid Phase
- Ethosomal drug delivery systems for skin cancer: Mechanistic insights, formulation strategies, and translational challenges.
- Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery
- Enteric polymers beyond protection: mechanistic insights and translational implications for supersaturating oral drug delivery systems
BibTeX
@article{deepika2026recent,
title = {{Recent insights into nanostructured lipid carriers for novel drug delivery systems}},
author = {Deepika and Yogita Tyagi and Anjali Bhatt and Robin Raj and Abhishek Kumar},
journal = {Journal of Applied Pharmaceutical Research},
year = {2026},
month = oct,
doi = {10.69857/joapr.v14i5.1932},
url = {https://doi.org/10.69857/joapr.v14i5.1932},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Recent insights into nanostructured lipid carriers for novel drug delivery systems
AU - Deepika
AU - Yogita Tyagi
AU - Anjali Bhatt
AU - Robin Raj
AU - Abhishek Kumar
PY - 2026
DA - 2026/10/01
JO - Journal of Applied Pharmaceutical Research
DO - 10.69857/joapr.v14i5.1932
UR - https://doi.org/10.69857/joapr.v14i5.1932
AB - Background: Nanostructured lipid carriers (NLCs) are advanced lipid-based nanocarriers developed to overcome the limitations of conventional drug-delivery systems. Composed of a nanometric matrix of solid and liquid lipids, NLCs offer improved stability, safety, and drug-loading efficiency compared with other lipid, polymeric, or metallic nanoparticles. Their biocompatibility and non-toxicity make them attractive for pharmaceutical and biomedical applications. Methodology: This review systematically summarizes recent literature on NLC design, classification, structural characteristics, and preparation techniques. It discusses widely used formulation methods for lipid-based nanocarriers and strategies for surface modification to achieve targeted delivery and prolonged residence time. Results and Discussion: Nanostructured lipid carriers (NLCs) show high drug encapsulation efficiency, typically 70–95%, about 20–30% higher than conventional solid lipid nanoparticles (SLNs). Furthermore, NLCs enhance physicochemical stability, improve permeability, and increase the solubility of both hydrophilic and lipophilic drugs. Surface functionalization strategies enable controlled drug release and targeted delivery, thereby significantly improving therapeutic outcomes across multiple routes of administration. Because they can enhance bioavailability and protect encapsulated agents, NLCs are particularly well-suited for challenging delivery routes. Their versatility supports applications across a wide range of diseases, including infections, diabetes, cancer, neurodegenerative disorders, hypertension, and pain management. Conclusion: Overall, NLCs are a promising, versatile platform for safe and effective drug and gene delivery. Continued research and optimization may further expand their clinical potential across diverse therapeutic areas.
SN - 2348-0335
ER -